查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095022

腫瘤學NGS（次世代定序）市場：全球市場預測（2026-2032）

Oncology NGS Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，腫瘤學領域的 NGS（次世代定序）市場將成長至 13.898 億美元，複合年成長率為 13.33%。

主要市場統計數據
基準年（2025 年） 5.7851億美元
預計年份（2026年） 6.5423億美元
預測年份（2032年） 13.898億美元
複合年成長率（） 13.33%

腫瘤次世代定序(NGS) 是精準腫瘤學的基礎技術，能夠識別臨床相關突變，支持治療方案選擇，在臨床試驗中進行患者分層，並透過全面的腫瘤基因組分析監測疾病進展。與單一基因檢測不同，腫瘤 NGS 可根據檢測設計並行評估多種生物標記物，包括單核苷酸多態性、插入和缺失、拷貝數變異、基因融合、微衛星不穩定性、腫瘤突變負荷、同源重組缺失以及新型表觀基因和轉錄組特徵。隨著肺癌、乳癌、大腸癌、攝護腺癌、骨髓惡性腫瘤惡性腫瘤和罕見癌症的治療逐漸轉向以生物標記主導的治療路徑，這種廣泛的評估能力的重要性日益凸顯。

目前，腫瘤學領域NGS的發展現狀受到以下因素的影響：全面基因組分析的廣泛應用、液態生物檢體的廣泛使用、標靶治療和免疫療法的日益普及，以及基因組數據整合到分子腫瘤學委員會中。當NGS結果與實證解讀、標準化報告、品管的檢測流程以及獲得適當治療和參與臨床試驗的機會相結合時，其臨床效用才能最大化。然而，由於保險報銷的複雜性、組織樣本合格認定方面的挑戰、檢測結果返回時間的差異、基因組檢測機會的不平等以及對強大的生物資訊基礎設施的需求，NGS的應用仍然不均衡。對於醫療保健系統、實驗室、保險公司和生命科學相關人員，策略重點不再是NGS在腫瘤學領域是否有價值，而是如何在整個癌症治療過程中持續、公平且負責任地應用NGS。

一項徹底改變腫瘤NGS前景的變革。

隨著診斷檢測的應用範圍從治療後期腫瘤特異性檢測轉向更廣泛的領域，例如診斷、復發監測和微量殘存疾病評估，腫瘤二代定序（NGS）的格局正在改變。全面的基因組分析正日益被納入多種晚期癌症的臨床指南，尤其是在非小細胞肺癌領域，適用於多種治療方案的生物標記會影響治療選擇。乳癌、卵巢、結直腸癌、前列腺癌、甲狀腺癌、黑色素瘤和血液腫瘤也呈現出類似的趨勢，基因組分析的洞見有助於確定標靶治療方案、闡明遺傳性癌症的關聯性以及確定臨床試驗的入組合格。

人工智慧對腫瘤NGS的累積影響

人工智慧正在對腫瘤學的整個NGS價值鏈產生累積影響，改善基因組數據的產生、解讀、報告以及在臨床決策中的應用。在檢查室工作流程中，人工智慧驅動的品管能夠識別定序偽影、檢體污染、缺失覆蓋和變異檢測不一致等問題。在生物資訊學領域，機器學習技術正被擴大用於輔助變異分類、結構突變檢測、拷貝數分析、融合基因識別、腫瘤純度評估以及臨床適用突變的優先排序。

腫瘤學NGS生態系的區域分析

在亞太地區，癌症發生率的上升、各國精準醫療舉措以及定序基礎設施的不斷完善，正推動著臨床需求的成長，進而促使新一代測序（NGS）技術在腫瘤學領域的應用迅速發展。中國、日本、韓國、印度、澳洲和新加坡正透過改善醫院檢測、建構研究網路以及完善伴隨診斷相關法規，不斷提升其在基因組腫瘤學領域的能力。儘管該地區在肺癌基因組學、遺傳性癌症檢測和液態生物檢體方面展現出強勁的發展勢頭，但都市區學術機構與偏遠地區在醫療資源取得方面仍存在顯著差距。

針對腫瘤引入NGS技術的主要群體特異性考量。

北約成員國與北美和歐洲先進的醫療保健體系高度重合，這些體系在腫瘤學領域採用新一代定序（NGS）技術得益於完善的檢查室品管框架、數據安全優先事項、規範的臨床路徑以及強大的生物醫學研究基礎設施。七國集團（G7）透過先進的監管體系、報銷模式、臨床指南制定、學術研究和大規模癌症舉措學計劃，共同影響腫瘤學領域NGS的標準。這些經濟體在伴隨診斷的完整性、分子腫瘤學委員會的成熟度、真實世界證據（REW）的開發以及將全面的基因組分析整合到癌症治療中發揮著尤為重要的作用。

主要國家腫瘤NGS檢測趨勢

在中國，由於國內創新和不斷累積的臨床證據，NGS技術已應用於肺癌、胃腸道腫瘤、遺傳性腫瘤和液態生物檢體等領域，並建構了相當可觀的定序能力。美國則憑藉著廣泛的生物標記主導型臨床指南、全面的基因組分析、活躍的臨床試驗網路以及完善的伴隨診斷路徑，引領NGS在腫瘤領域的應用。日本已將全面的基因組分析正式納入晚期癌症治療的臨床路徑，強調基於監管的檢測、專家解讀以及與臨床試驗的合作。在印度，受癌症發病率上升、私人診斷網路發展以及臨床醫生接受度提高的推動，NGS在腫瘤領域的應用正在大都會圈癌症中心迅速擴展，但成本效益和醫保報銷仍然是主要障礙。

為腫瘤學領域NGS產業領導者提供的實用建議

產業領導者應優先產生臨床層級證據，證明腫瘤NGS如何改善特定癌症類型和醫療環境下的治療選擇、臨床試驗配對、疾病監測和患者預後。實驗室和醫療機構需要簡化分析前流程，以緩解組織短缺問題，規範檢體處理，並縮短結果獲取時間。推廣指南支援的生物標記反射性檢測方案，可以減少延誤，並確保在製定治療決策之前獲得可操作的基因組資訊。

用於腫瘤NGS分析的分析方法

本報告採用系統性的二手調查方法編製而成，重點在於權威資訊來源中與腫瘤學和精準癌症診斷相關的、檢驗且有數據支持的見解。該研究途徑強調同行評審的科學文獻、臨床實踐指南、監管出版刊物、公共衛生機構資源、腫瘤學和病理學專業學會的指導意見、衛生技術評估 (HTA) 文件以及國家基因組醫學舉措中發布的信息。報告優先考慮提及分析有效性、臨床有效性、臨床效用、保險報銷考慮因素、監管要求、生物標記應用以及區域應用趨勢的資訊來源。

結論：腫瘤NGS是精準腫瘤治療的核心。

腫瘤NGS技術透過更全面、更精準、更具臨床應用價值地了解腫瘤的生物學特徵，正在重新定義癌症診斷。其作用不僅限於識別單一突變，還能透過全面的基因組分析、液態生物檢體、治療抗藥性監測、遺傳風險評估和臨床試驗配對等方式，支持癌症的綜合管理。隨著循證依證的不斷積累，腫瘤NGS技術在精準腫瘤學計畫中正日益普及，但其影響力取決於公平的獲取途徑、高品質的檢測、檢驗的解讀以及與現有治療方案的匹配。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：人工智慧（AI）的累積影響（2026 年）

第7章 腫瘤NGS市場：依產品類型分類

  • 裝置
  • 試劑和耗材
    • 樣品製備工具包
    • 定序試劑
    • 目標富集試劑盒
  • 服務
    • 生物資訊數據分析服務
    • 臨床報告與解釋服務

第8章：腫瘤NGS市場：依癌症類型分類

  • 固體癌
    • 乳癌
    • 肺癌
    • 結腸癌
    • 攝護腺癌
    • 卵巢癌
    • 黑色素瘤
  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤

第9章：腫瘤學領域NGS市場：依技術分類

  • 全基因測序
  • 全EXOME定序
  • 標靶定序和定序

第10章 腫瘤NGS市場：依檢體類型分類

  • 組織檢體
    • 福馬林固定石蠟包埋組織
    • 活體冷凍組織
  • 液態生物檢體樣本
    • 電漿
    • 血清
    • 循環性腫瘤細胞

第11章：腫瘤學領域NGS市場：依工作流程階段分類

  • 定序前
  • 定序
  • 數據分析

第12章 腫瘤學領域的NGS市場：依應用領域分類

  • 臨床診斷
    • 固態腫瘤的特徵分析
    • 骨髓惡性腫瘤的分析
    • 生殖系細胞株易感性檢測
    • 微量殘存疾病的監測
    • 伴隨診斷
  • 分析
    • 腫瘤生物標記的發現
    • 腫瘤異質性研究
    • 藥物抗藥性機制研究
  • 藥物研發
  • 液態生物檢體
    • 癌症早期發現
    • 治療反應監測
    • 復發監測

第13章：腫瘤學領域的NGS市場：依最終用戶分類

  • 學術和研究機構
  • 醫院和癌症中心
    • 腫瘤學
    • 病理檢查室
  • 臨床/診斷檢查室
  • 製藥和生物技術公司
  • CRO（委外研發機構）

第14章 腫瘤領域NGS市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第15章：腫瘤學領域NGS市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第16章 腫瘤學領域NGS市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第17章 競爭格局

  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）

第18章：公司簡介

  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • Burning Rock Dx
  • Creative Biogene
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genecast Group Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Macrogen, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Oxford Nanopore Technologies plc.
  • Pacific Biosciences of California, Inc.
  • PerkinElmer Inc.
  • Personalis, Inc.
  • Promega Corporation
  • Qiagen NV
  • SOPHiA GENETICS.
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • Twist Bioscience Corporation
Product Code: MRR-3A2E844FECAB

The Oncology NGS Market is projected to grow by USD 1,389.80 million at a CAGR of 13.33% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 578.51 million
Estimated Year [2026] USD 654.23 million
Forecast Year [2032] USD 1,389.80 million
CAGR (%) 13.33%

Oncology next-generation sequencing (NGS) has become a foundational technology in precision oncology, enabling comprehensive genomic profiling of tumors to identify clinically relevant alterations, support therapy selection, stratify patients for clinical trials, and monitor disease evolution. Unlike single-gene assays, oncology NGS can evaluate multiple biomarkers in parallel, including single nucleotide variants, insertions and deletions, copy number alterations, gene fusions, microsatellite instability, tumor mutational burden, homologous recombination deficiency, and emerging epigenomic or transcriptomic signatures, depending on assay design. This breadth is increasingly important as cancer care moves toward biomarker-driven treatment pathways across lung cancer, breast cancer, colorectal cancer, prostate cancer, hematologic malignancies, and rare tumor types.

The oncology NGS landscape is shaped by rising adoption of comprehensive genomic profiling, broader use of liquid biopsy, increasing availability of targeted therapies and immunotherapies, and growing integration of genomic data into molecular tumor boards. Clinical utility is strongest when NGS results are linked to evidence-based interpretation, standardized reporting, quality-controlled laboratory workflows, and access to appropriate therapies or trials. At the same time, implementation remains uneven because of reimbursement complexity, tissue adequacy challenges, variable test turnaround times, disparities in genomic testing access, and the need for robust bioinformatics infrastructure. For healthcare systems, laboratories, payers, and life sciences stakeholders, the strategic priority is no longer whether oncology NGS is valuable, but how to deploy it consistently, equitably, and responsibly across the cancer care continuum.

Transformative Shifts Reshaping the Oncology NGS Landscape

The oncology NGS environment is undergoing transformative shifts as testing moves from late-line, tumor-specific use toward broader applications at diagnosis, relapse, and minimal residual disease assessment. Comprehensive genomic profiling is increasingly embedded in clinical guidelines for several advanced cancers, especially non-small cell lung cancer, where multiple actionable biomarkers influence treatment selection. Similar momentum is visible in breast, ovarian, colorectal, prostate, thyroid, melanoma, and hematologic cancers, where genomic insights help identify targeted therapy options, hereditary cancer implications, and trial eligibility.

Liquid biopsy is one of the most significant shifts, offering a less invasive route to detect circulating tumor DNA when tissue is limited, inaccessible, or insufficient. It is also supporting resistance monitoring and molecular relapse detection, although sensitivity varies by tumor type, disease burden, assay methodology, and sample handling. Another major transition is the expansion from DNA-only panels to integrated multi-omics approaches that combine DNA, RNA, methylation, fragmentomics, proteomics, or immune profiling to improve detection of fusions, expression signatures, and complex biomarkers. Meanwhile, decentralized and hybrid testing models are emerging, with some health systems building in-house NGS capabilities while others rely on reference laboratories for scale, assay breadth, and specialized interpretation.

Regulatory and clinical evidence expectations are also becoming more stringent. Laboratories must demonstrate analytical validity, clinical validity, and clinical utility while maintaining compliance with quality standards, data privacy obligations, and evolving companion diagnostic requirements. The future of oncology NGS will be defined by interoperability, faster turnaround, longitudinal testing, equitable access, and the ability to translate complex genomic findings into actionable cancer treatment decisions.

Cumulative Impact of Artificial Intelligence on Oncology NGS

Artificial intelligence is becoming a cumulative force across the oncology NGS value chain, improving how genomic data are generated, interpreted, reported, and applied in clinical decision-making. In laboratory workflows, AI-assisted quality control can help identify sequencing artifacts, sample contamination, coverage gaps, and variant-calling inconsistencies. In bioinformatics, machine learning methods are increasingly used to support variant classification, structural variant detection, copy number analysis, fusion discovery, tumor purity estimation, and prioritization of clinically actionable alterations.

The greatest impact of AI in oncology NGS is emerging at the interpretation layer, where the volume and complexity of molecular findings can exceed manual review capacity. AI-enabled knowledge systems can map variants to curated evidence, clinical guidelines, drug labels, resistance mechanisms, and clinical trial eligibility criteria. Natural language processing can assist in extracting information from pathology reports, electronic health records, scientific literature, and trial registries, supporting more complete molecular tumor board review. In liquid biopsy and minimal residual disease applications, AI models may improve signal detection by integrating genomic patterns with fragment size, methylation markers, and longitudinal patient data.

However, AI adoption in oncology NGS must be governed carefully. Algorithms require transparent validation, representative training data, bias monitoring, version control, and explainable outputs suitable for clinical review. AI should augment, not replace, molecular pathologists, oncologists, geneticists, and laboratory professionals. Its long-term value will depend on clinical-grade evidence, reproducibility across populations, secure data infrastructure, and integration into regulated workflows that protect patient privacy while enabling precision oncology at scale.

Key Regional Insights Across the Oncology NGS Ecosystem

Asia-Pacific is advancing rapidly in oncology NGS adoption as cancer incidence, national precision medicine initiatives, and expanding sequencing infrastructure drive clinical demand. China, Japan, South Korea, India, Australia, and Singapore are strengthening genomic oncology capabilities through hospital-based testing, research networks, and regulatory pathways for companion diagnostics. The region shows strong momentum in lung cancer genomics, hereditary cancer testing, and liquid biopsy, though access varies widely between urban academic centers and underserved areas.

Europe is shaped by strong public health systems, cross-border research initiatives, national genomic medicine programs, and regulatory focus on in vitro diagnostics, data protection, and clinical evidence. Countries such as Germany, France, the United Kingdom, Italy, and Spain are expanding genomic testing through national or regional programs while addressing harmonization of reimbursement, laboratory standards, and molecular tumor board integration. North America remains one of the most mature regions for oncology NGS because of guideline-driven biomarker testing, established laboratory accreditation frameworks, broad clinical trial activity, advanced oncology networks, and growing payer engagement with comprehensive genomic profiling. The United States is particularly influential in tumor-agnostic biomarker adoption, companion diagnostic development, and real-world evidence generation, while Canada continues to expand provincial genomic testing programs with an emphasis on equitable access and health system integration.

Latin America is experiencing gradual expansion in oncology NGS, supported by increasing awareness of precision oncology, stronger private-sector testing availability, and regional oncology collaborations. Brazil and Mexico are central to regional progress, but reimbursement limitations, fragmented healthcare systems, limited molecular pathology capacity, and uneven access to targeted therapies continue to affect routine implementation. Africa is at an earlier stage of oncology NGS deployment, with access concentrated in select academic, private, and international collaboration settings. Major priorities include pathology capacity, sample logistics, sequencing infrastructure, workforce training, ethical genomic governance, and inclusion of African genomic diversity in cancer research. The Middle East is investing in precision medicine infrastructure, with GCC countries emphasizing advanced oncology centers, genomic databases, and tertiary care capabilities. Adoption is strongest in specialized hospitals, supported by government healthcare modernization strategies, although workforce development and standardized reimbursement remain important.

Key Group Insights for Oncology NGS Adoption

NATO countries overlap substantially with advanced North American and European healthcare systems, where oncology NGS adoption is supported by laboratory quality frameworks, data security priorities, regulated clinical pathways, and strong biomedical research infrastructure. The G7 countries collectively influence oncology NGS standards through advanced regulatory systems, reimbursement models, clinical guideline development, academic research, and large-scale cancer genomics initiatives. These economies are particularly important in companion diagnostic alignment, molecular tumor board maturity, real-world evidence development, and integration of comprehensive genomic profiling into cancer care.

BRICS countries represent a diverse and strategically significant group for oncology NGS. China and India are expanding sequencing capacity and clinical genomics programs, Brazil is strengthening precision oncology access in Latin America, Russia maintains specialized oncology and genetics capabilities despite system-level constraints, and South Africa plays an important role in genomic research and regional oncology capacity building. The European Union provides a highly structured environment for oncology NGS through regulatory oversight, cross-country research networks, health technology assessment, cancer mission initiatives, and data governance frameworks. The EU's emphasis on interoperability, evidence generation, and equitable cancer care supports broader adoption, although reimbursement decisions and implementation models remain country-specific.

ASEAN is emerging as an important growth arena for oncology NGS as Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines expand cancer diagnostics infrastructure at different speeds. Singapore is a regional leader in genomic medicine, while broader ASEAN adoption is influenced by affordability, laboratory capacity, clinician education, and access to targeted oncology therapies. The GCC is prioritizing oncology NGS within broader precision medicine and healthcare transformation strategies. Countries in the group are investing in advanced cancer centers, genomic data initiatives, and high-acuity tertiary care, creating opportunities for comprehensive genomic profiling and liquid biopsy integration. Across all groups, the decisive factors are reimbursement clarity, clinical utility evidence, workforce capability, data interoperability, and patient access to matched therapies.

Key Country Insights in Oncology NGS

China has built substantial sequencing capacity and is applying oncology NGS across lung cancer, gastrointestinal cancers, hereditary cancer, and liquid biopsy, supported by domestic innovation and expanding clinical evidence generation. The United States leads in oncology NGS implementation through extensive biomarker-driven clinical guidelines, broad availability of comprehensive genomic profiling, active clinical trial networks, and established pathways for companion diagnostics. Japan has formalized comprehensive genomic profiling within advanced cancer care pathways and emphasizes regulated testing, expert interpretation, and linkage to clinical trials. India is rapidly increasing use of oncology NGS in metropolitan cancer centers, with demand driven by rising cancer burden, private diagnostic networks, and growing clinician adoption, although affordability and reimbursement remain central barriers.

Germany benefits from strong molecular pathology expertise, certified laboratories, and reimbursement mechanisms for selected genomic applications. The United Kingdom has advanced national genomic testing infrastructure and integrated genomic laboratory networks that support standardized cancer testing. Australia has strong clinical genomics programs, population-level precision oncology initiatives, and well-developed laboratory quality systems. France has long-standing national molecular oncology networks and continues to strengthen comprehensive genomic profiling through structured public programs. South Korea is advancing oncology NGS through national reimbursement mechanisms for selected panels, technologically sophisticated hospitals, and strong integration of molecular diagnostics into cancer care.

Italy and Spain are expanding tumor genomic testing through regional health systems, molecular tumor boards, and increasing alignment with European oncology guidelines. Canada is expanding access through provincial health systems and national precision oncology collaborations, with an emphasis on evidence-based reimbursement and equitable testing. Russia has oncology genetics capabilities in major centers, but access and integration vary across regions. Brazil is the most prominent oncology NGS environment in Latin America, supported by large cancer centers, academic research activity, and rising precision oncology awareness, though public-sector access remains uneven. Mexico is increasing adoption in major cancer centers, particularly for lung, breast, colorectal, and hereditary cancer applications, while broader access remains shaped by payer fragmentation and infrastructure gaps.

Actionable Recommendations for Oncology NGS Industry Leaders

Industry leaders should prioritize clinical-grade evidence generation that demonstrates how oncology NGS improves treatment selection, trial matching, disease monitoring, and patient outcomes across specific tumor types and care settings. Laboratories and healthcare providers should streamline pre-analytical workflows to reduce tissue insufficiency, standardize sample handling, and improve turnaround times. Expanding reflex testing protocols for guideline-supported biomarkers can reduce delays and ensure that actionable genomic information is available before treatment decisions are made.

Stakeholders should invest in interoperable bioinformatics platforms, structured reporting, and decision support tools that connect genomic findings with therapy labels, guidelines, resistance data, and clinical trial options. Payers and health systems should develop reimbursement policies based on clinical utility, test quality, and appropriate use criteria, while also supporting equitable access for underserved populations. Oncology networks should strengthen molecular tumor boards, genetic counseling pathways, and clinician education to ensure that NGS results are interpreted correctly and translated into care.

For liquid biopsy and minimal residual disease applications, leaders should define clear use cases, validation standards, and longitudinal testing protocols. Data governance must be treated as a strategic priority, with secure infrastructure, consent frameworks, privacy safeguards, and responsible AI oversight. Organizations that combine validated assays, robust interpretation, real-world evidence, and patient-centered access models will be best positioned to advance precision oncology responsibly.

Research Methodology for Oncology NGS Analysis

This executive summary is developed using a structured secondary research methodology focused on verified, data-backed insights from authoritative sources relevant to oncology NGS and precision cancer diagnostics. The research approach emphasizes peer-reviewed scientific literature, clinical practice guidelines, regulatory publications, public health agency resources, professional oncology and pathology society guidance, health technology assessment documents, and publicly available information from national genomic medicine initiatives. Priority is given to sources that address analytical validity, clinical validity, clinical utility, reimbursement considerations, regulatory requirements, biomarker adoption, and regional implementation trends.

The methodology includes triangulation across multiple evidence categories to avoid reliance on single-source conclusions. Clinical insights are assessed in relation to established cancer care pathways, biomarker testing recommendations, companion diagnostic use, and molecular tumor board practices. Regional, group, and country-level insights are synthesized by evaluating healthcare infrastructure, genomic medicine policies, laboratory capacity, reimbursement environments, data governance maturity, and access to targeted therapies or immunotherapies. No market sizing, market share, or forecasting assumptions are used. The analysis is designed to provide decision-ready strategic intelligence for stakeholders seeking to understand oncology NGS adoption dynamics, implementation barriers, and evidence-based opportunities across global healthcare systems.

Conclusion: Oncology NGS as a Core Engine of Precision Oncology

Oncology NGS is redefining cancer diagnostics by enabling a more comprehensive, precise, and clinically actionable understanding of tumor biology. Its role now extends beyond identifying individual mutations to supporting integrated cancer management through comprehensive genomic profiling, liquid biopsy, therapy resistance monitoring, hereditary risk assessment, and clinical trial matching. As the evidence base grows, oncology NGS is becoming increasingly embedded in precision oncology programs, but its impact depends on equitable access, high-quality testing, validated interpretation, and alignment with treatment availability.

The next phase of oncology NGS will be shaped by multi-omics integration, AI-assisted interpretation, improved liquid biopsy performance, stronger regulatory oversight, and deeper use of real-world evidence. Regions and health systems that invest in laboratory quality, reimbursement clarity, clinician education, data interoperability, and responsible governance will be better positioned to translate genomic insights into measurable clinical value. For industry leaders, the strategic imperative is to move beyond test availability and focus on building reliable, scalable, and patient-centered precision oncology ecosystems that connect genomic information to better cancer care decisions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oncology NGS Market, by Product Type

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents & Consumables
    • 7.3.1. Library Preparation Kits
    • 7.3.2. Sequencing Reagents
    • 7.3.3. Target Enrichment Kits
  • 7.4. Services
    • 7.4.1. Bioinformatics & Data Analysis Services
    • 7.4.2. Clinical Reporting & Interpretation Services

8. Oncology NGS Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Solid Tumors
    • 8.2.1. Breast Cancer
    • 8.2.2. Lung Cancer
    • 8.2.3. Colorectal Cancer
    • 8.2.4. Prostate Cancer
    • 8.2.5. Ovarian Cancer
    • 8.2.6. Melanoma
  • 8.3. Hematologic Malignancies
    • 8.3.1. Leukemia
    • 8.3.2. Lymphoma
    • 8.3.3. Myeloma

9. Oncology NGS Market, by Technology

  • 9.1. Introduction
  • 9.2. Whole Genome Sequencing
  • 9.3. Whole Exome Sequencing
  • 9.4. Targeted Sequencing & Resequencing

10. Oncology NGS Market, by Sample Type

  • 10.1. Introduction
  • 10.2. Tissue Samples
    • 10.2.1. Formalin-Fixed Paraffin-Embedded Tissue
    • 10.2.2. Fresh Frozen Tissue
  • 10.3. Liquid Biopsy Samples
    • 10.3.1. Plasma
    • 10.3.2. Serum
    • 10.3.3. Circulating Tumor Cells

11. Oncology NGS Market, by Workflow Stage

  • 11.1. Introduction
  • 11.2. Pre-Sequencing
  • 11.3. Sequencing
  • 11.4. Data Analysis

12. Oncology NGS Market, by Application

  • 12.1. Introduction
  • 12.2. Clinical Diagnostics
    • 12.2.1. Solid Tumor Profiling
    • 12.2.2. Hematologic Malignancy Profiling
    • 12.2.3. Germline Cancer Predisposition Testing
    • 12.2.4. Minimal Residual Disease Monitoring
    • 12.2.5. Companion Diagnostics
  • 12.3. Research
    • 12.3.1. Oncology Biomarker Discovery
    • 12.3.2. Tumor Heterogeneity Studies
    • 12.3.3. Resistance Mechanism Studies
  • 12.4. Drug Development
  • 12.5. Liquid Biopsy
    • 12.5.1. Early Cancer Detection
    • 12.5.2. Treatment Response Monitoring
    • 12.5.3. Recurrence Surveillance

13. Oncology NGS Market, by End User

  • 13.1. Introduction
  • 13.2. Academic & Research Institutions
  • 13.3. Hospitals & Cancer Centers
    • 13.3.1. Oncology Departments
    • 13.3.2. Pathology Laboratories
  • 13.4. Clinical Diagnostic Laboratories
  • 13.5. Pharmaceutical & Biotechnology Companies
  • 13.6. Contract Research Organizations

14. Oncology NGS Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. Europe
  • 14.3. North America
  • 14.4. Latin America
  • 14.5. Africa
  • 14.6. Middle East

15. Oncology NGS Market, by Group

  • 15.1. NATO
  • 15.2. G7
  • 15.3. BRICS
  • 15.4. European Union
  • 15.5. ASEAN
  • 15.6. GCC

16. Oncology NGS Market, by Country

  • 16.1. China
  • 16.2. United States
  • 16.3. Japan
  • 16.4. India
  • 16.5. Germany
  • 16.6. United Kingdom
  • 16.7. Australia
  • 16.8. France
  • 16.9. South Korea
  • 16.10. Italy
  • 16.11. Canada
  • 16.12. Russia
  • 16.13. Brazil
  • 16.14. Mexico
  • 16.15. Spain

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2025
  • 17.2. FPNV Positioning Matrix, 2025
  • 17.3. Market Concentration Analysis, 2025
    • 17.3.1. Concentration Ratio (CR)
    • 17.3.2. Herfindahl Hirschman Index (HHI)
  • 17.4. Recent Developments & Impact Analysis, 2025
  • 17.5. Product Portfolio Analysis, 2025
  • 17.6. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. Agilent Technologies, Inc.
  • 18.2. BGI Group
  • 18.3. Bio-Rad Laboratories, Inc.
  • 18.4. Burning Rock Dx
  • 18.5. Creative Biogene
  • 18.6. Eurofins Scientific S.E.
  • 18.7. Exact Sciences Corporation
  • 18.8. F. Hoffmann-La Roche Ltd.
  • 18.9. Genecast Group Inc.
  • 18.10. Guardant Health, Inc.
  • 18.11. Hologic, Inc.
  • 18.12. Illumina, Inc.
  • 18.13. Invivoscribe, Inc.
  • 18.14. Macrogen, Inc.
  • 18.15. Myriad Genetics, Inc.
  • 18.16. Natera, Inc.
  • 18.17. Oxford Nanopore Technologies plc.
  • 18.18. Pacific Biosciences of California, Inc.
  • 18.19. PerkinElmer Inc.
  • 18.20. Personalis, Inc.
  • 18.21. Promega Corporation
  • 18.22. Qiagen N.V.
  • 18.23. SOPHiA GENETICS.
  • 18.24. Takara Bio Inc.
  • 18.25. Thermo Fisher Scientific, Inc.
  • 18.26. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLOGY NGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ONCOLOGY NGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ONCOLOGY NGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ONCOLOGY NGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL ONCOLOGY NGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ONCOLOGY NGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 27. GLOBAL ONCOLOGY NGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLOGY NGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ONCOLOGY NGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIBRARY PREPARATION KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIBRARY PREPARATION KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIBRARY PREPARATION KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SEQUENCING REAGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGET ENRICHMENT KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGET ENRICHMENT KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGET ENRICHMENT KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOINFORMATICS & DATA ANALYSIS SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CLINICAL REPORTING & INTERPRETATION SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CLINICAL REPORTING & INTERPRETATION SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CLINICAL REPORTING & INTERPRETATION SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SOLID TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SOLID TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SOLID TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BREAST CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BREAST CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BREAST CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COLORECTAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLORECTAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLORECTAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PROSTATE CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PROSTATE CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PROSTATE CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OVARIAN CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OVARIAN CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OVARIAN CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MELANOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MELANOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MELANOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HEMATOLOGIC MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MYELOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MYELOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MYELOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL WHOLE GENOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL WHOLE EXOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED SEQUENCING & RESEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED SEQUENCING & RESEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED SEQUENCING & RESEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TISSUE SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TISSUE SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TISSUE SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL FRESH FROZEN TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL FRESH FROZEN TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL FRESH FROZEN TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LIQUID BIOPSY SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIQUID BIOPSY SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LIQUID BIOPSY SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CIRCULATING TUMOR CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PRE-SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PRE-SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRE-SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DATA ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DATA ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DATA ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL SOLID TUMOR PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL SOLID TUMOR PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL SOLID TUMOR PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HEMATOLOGIC MALIGNANCY PROFILING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HEMATOLOGIC MALIGNANCY PROFILING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HEMATOLOGIC MALIGNANCY PROFILING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GERMLINE CANCER PREDISPOSITION TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GERMLINE CANCER PREDISPOSITION TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GERMLINE CANCER PREDISPOSITION TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MINIMAL RESIDUAL DISEASE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MINIMAL RESIDUAL DISEASE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MINIMAL RESIDUAL DISEASE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLOGY BIOMARKER DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONCOLOGY BIOMARKER DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLOGY BIOMARKER DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL TUMOR HETEROGENEITY STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL TUMOR HETEROGENEITY STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL TUMOR HETEROGENEITY STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL RESISTANCE MECHANISM STUDIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL RESISTANCE MECHANISM STUDIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL RESISTANCE MECHANISM STUDIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL DRUG DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL LIQUID BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL EARLY CANCER DETECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL EARLY CANCER DETECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL EARLY CANCER DETECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL TREATMENT RESPONSE MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL RECURRENCE SURVEILLANCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL RECURRENCE SURVEILLANCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL RECURRENCE SURVEILLANCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ACADEMIC & RESEARCH INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL HOSPITALS & CANCER CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL HOSPITALS & CANCER CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL HOSPITALS & CANCER CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ONCOLOGY DEPARTMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ONCOLOGY DEPARTMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ONCOLOGY DEPARTMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL PATHOLOGY LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL PATHOLOGY LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL PATHOLOGY LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL CLINICAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL CLINICAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL CLINICAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ONCOLOGY NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ONCOLOGY NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA ONCOLOGY NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 263. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 264. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 266. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 267. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 270. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 274. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 278. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. MIDDLE EAST ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 281. GLOBAL ONCOLOGY NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 282. NATO ONCOLOGY NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 283. NATO ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. NATO ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 285. NATO ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 286. NATO ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 288. NATO ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 289. NATO ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. NATO ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. NATO ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 292. NATO ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 294. NATO ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 295. NATO ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 296. NATO ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 297. NATO ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 298. NATO ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. NATO ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 300. G7 ONCOLOGY NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 301. G7 ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. G7 ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 303. G7 ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 304. G7 ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 305. G7 ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 306. G7 ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 307. G7 ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. G7 ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. G7 ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 310. G7 ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 311. G7 ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 312. G7 ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 313. G7 ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 314. G7 ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 315. G7 ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 316. G7 ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. G7 ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS ONCOLOGY NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 334. BRICS ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 335. BRICS ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 336. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 337. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 339. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 340. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 341. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 342. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 343. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 344. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 346. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 347. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 348. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 349. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 350. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 351. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 352. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 353. EUROPEAN UNION ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 354. ASEAN ONCOLOGY NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 355. ASEAN ONCOLOGY NGS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 356. ASEAN ONCOLOGY NGS MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 357. ASEAN ONCOLOGY NGS MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 358. ASEAN ONCOLOGY NGS MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 359. ASEAN ONCOLOGY NGS MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 360. ASEAN ONCOLOGY NGS MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 361. ASEAN ONCOLOGY NGS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 362. ASEAN ONCOLOGY NGS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 363. ASEAN ONCOLOGY NGS MARKET SIZE, BY TISSUE SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 364. ASEAN ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY SAMPLES, 2018-2032 (USD MILLION)
  • TABLE 365. ASEAN ONCOLOGY NGS MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 366. ASEAN ONCOLOGY NGS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 367. ASEAN ONCOLOGY NGS MARKET SIZE, BY CLINICAL DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 368. ASEAN ONCOLOGY NGS MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 369. ASEAN ONCOLOGY NGS MARKET SIZE, BY LIQUID BIOPSY, 2018-2032 (USD MILLION)
  • TABLE 370. ASEAN ONCOLOGY NGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 371. ASEAN ONCOLOGY NGS MARKET SIZE, BY HOSPITALS & CANCER CENTERS, 2018-2032 (USD MILLION)
  • TABLE 372. GCC ONCOLOGY NGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)

TABLE 373.